Research programme: immunocytokine fusion proteins - Peregrine/Biotecnol
Latest Information Update: 14 Jun 2012
At a glance
- Originator Biotecnol SA; Peregrine Pharmaceuticals
- Class Antibodies; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Vascular disrupting agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 11 Oct 2010 No development reported for Solid tumours in Portugal (Parenteral)
- 14 Dec 2006 Preclinical in Solid tumours in Portugal (Parenteral)